CN110869015B - 用于治疗神经炎性紊乱的有机小分子 - Google Patents

用于治疗神经炎性紊乱的有机小分子 Download PDF

Info

Publication number
CN110869015B
CN110869015B CN201880043208.8A CN201880043208A CN110869015B CN 110869015 B CN110869015 B CN 110869015B CN 201880043208 A CN201880043208 A CN 201880043208A CN 110869015 B CN110869015 B CN 110869015B
Authority
CN
China
Prior art keywords
group
bmp
compound
cells
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880043208.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN110869015A (zh
Inventor
阿尔农·卡尔尼
卡琳·伯纳特·法因伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Infrastructure and Health Services Fund of the Tel Aviv Medical Center
Original Assignee
Medical Research Infrastructure and Health Services Fund of the Tel Aviv Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Infrastructure and Health Services Fund of the Tel Aviv Medical Center filed Critical Medical Research Infrastructure and Health Services Fund of the Tel Aviv Medical Center
Publication of CN110869015A publication Critical patent/CN110869015A/zh
Application granted granted Critical
Publication of CN110869015B publication Critical patent/CN110869015B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/345—Nitrofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201880043208.8A 2017-04-26 2018-04-26 用于治疗神经炎性紊乱的有机小分子 Active CN110869015B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL251949A IL251949A0 (en) 2017-04-26 2017-04-26 Small organic molecules for use in the treatment of neuro-inflammatory diseases
IL251949 2017-04-26
PCT/IL2018/050463 WO2018198123A1 (en) 2017-04-26 2018-04-26 Small organic molecules for use in the treatment of neuroinflammatory disorders

Publications (2)

Publication Number Publication Date
CN110869015A CN110869015A (zh) 2020-03-06
CN110869015B true CN110869015B (zh) 2023-08-18

Family

ID=62454780

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880043208.8A Active CN110869015B (zh) 2017-04-26 2018-04-26 用于治疗神经炎性紊乱的有机小分子

Country Status (9)

Country Link
US (2) US11103479B2 (https=)
EP (1) EP3615022B1 (https=)
JP (1) JP6997800B2 (https=)
CN (1) CN110869015B (https=)
AU (1) AU2018260535B2 (https=)
CA (1) CA3061296A1 (https=)
ES (1) ES2948767T3 (https=)
IL (2) IL251949A0 (https=)
WO (1) WO2018198123A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019122202A1 (en) * 2017-12-20 2019-06-27 Ecole Polytechnique Federale De Lausanne (Epfl) Sting inhibitors
JP7481329B2 (ja) * 2018-06-07 2024-05-10 ディスアーム セラピューティクス， インコーポレイテッド Ｓａｒｍ１阻害剤
WO2020132045A1 (en) * 2018-12-19 2020-06-25 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013186777A2 (en) * 2012-06-14 2013-12-19 The Medical Researth, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Use of blocking agents of bone morphogenie protein (bmp) signaling for the treatment of neuroinflammatory and neurodegenerative diseases

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY109202A (en) 1992-07-10 1996-12-31 Nihon Nohyaku Co Ltd Isothiazole derivatives and processes for preparing the same as well as termite controlling agents comprising the same as active ingredient
IT1313601B1 (it) 1999-08-05 2002-09-09 Isagro Ricerca Srl Fenilpirazoli ad attivita' erbicida
EP1088822A1 (en) * 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl hydrazide derivatives
US6989451B2 (en) 2002-06-04 2006-01-24 Valeant Research & Development Heterocyclic compounds and uses thereof
US6727241B2 (en) * 2002-06-12 2004-04-27 Chemocentryx Anti-inflammatory compositions and methods of use
GB0306357D0 (en) 2003-03-20 2003-04-23 Astrazeneca Ab Chemical compounds
US20080249038A1 (en) 2003-10-07 2008-10-09 Quark Biotech, Inc. Bone Morphogenetic Protein (Bmp) 2A and Uses Thereof
US20060217390A1 (en) 2005-02-24 2006-09-28 Esmir Gunic Cycloalkl, aryl and heteroaryl amino isothiazoles for the treatment of Hepatitis C virus
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
CN100396667C (zh) * 2006-02-20 2008-06-25 中国医学科学院医药生物技术研究所 一组具有上调骨形成蛋白bmp-2表达活性的五元不饱和杂环化合物
US8497272B2 (en) * 2006-08-21 2013-07-30 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
WO2008118626A2 (en) 2007-03-08 2008-10-02 Burnham Institute For Medical Research Inhibitors of jnk and methods for identifying inhibitors of jnk
JP5638961B2 (ja) * 2008-03-13 2014-12-10 ザ ジェネラル ホスピタル コーポレイション Ｂｍｐシグナル伝達経路のインヒビター
EP2453882A1 (en) * 2009-07-14 2012-05-23 Beth Israel Deaconess Medical Center, Inc. Methods of increasing liver proliferation
US20110039900A1 (en) 2009-08-11 2011-02-17 Allergan, Inc. Isothiozoles for treating conditions of the eye
JP5725469B2 (ja) * 2010-11-15 2015-05-27 学校法人北里研究所 骨分化阻害剤およびその製造方法
US9682983B2 (en) * 2013-03-14 2017-06-20 The Brigham And Women's Hospital, Inc. BMP inhibitors and methods of use thereof
US20160045609A1 (en) 2014-08-14 2016-02-18 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013186777A2 (en) * 2012-06-14 2013-12-19 The Medical Researth, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Use of blocking agents of bone morphogenie protein (bmp) signaling for the treatment of neuroinflammatory and neurodegenerative diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PUBchem.Methyl 3-[(2E)-2-[cyano(thiophen-2-ylsulfonyl)methylidene]hydrazinyl]thiophene一2-carboxylate.《PUBchem》.2005,1-11. *

Also Published As

Publication number Publication date
IL269894B (en) 2022-03-01
US20210393582A1 (en) 2021-12-23
JP6997800B2 (ja) 2022-02-04
CA3061296A1 (en) 2018-11-01
EP3615022B1 (en) 2023-06-07
ES2948767T3 (es) 2023-09-18
EP3615022A4 (en) 2021-03-31
IL251949A0 (en) 2017-07-31
US11779565B2 (en) 2023-10-10
US11103479B2 (en) 2021-08-31
CN110869015A (zh) 2020-03-06
EP3615022C0 (en) 2023-06-07
AU2018260535A1 (en) 2019-10-31
US20200046680A1 (en) 2020-02-13
JP2020517678A (ja) 2020-06-18
EP3615022A1 (en) 2020-03-04
WO2018198123A1 (en) 2018-11-01
AU2018260535B2 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
US9469653B2 (en) Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same
EP3425390B1 (en) Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same
JP2010528016A (ja) 細胞を刺激するための方法および組成物
EP2806948B1 (en) Method for enhancing remyelination using gli1 inhibitors
US11779565B2 (en) Small organic molecules for use in the treatment of neuroinflammatory disorders
US9028810B2 (en) Composition for inducing migration of neural stem cells containing periostin as effective ingredient
US20030082802A1 (en) Method for neural stem cell differentiation using 5ht1a agonists
CN116397021A (zh) PPP4r3a和/或Kif2a在进行性核上性麻痹诊治中的应用
US20070149580A1 (en) Use of peroxisome proliferator activated receptor delta agonists for the treatment of ms and other demyelinating diseases
Chen et al. Artemisinin alleviates astrocyte overactivation and neuroinflammation by modulating the IRE1/NF-κB signaling pathway in in vitro and in vivo Alzheimer's disease models
JP2020500197A (ja) 骨格筋肥大誘発剤としてのｌｓｄ１阻害剤
JP2026026410A (ja) 神経筋接合部の保護及び／又は再生剤
WO2025249409A1 (ja) 髄鞘異常関連疾患治療剤の有効成分として有用な化合物
EA038404B1 (ru) Применение траметиниба для лечения нейродегенеративного заболевания, вызванного утратой или повреждением нейронов
HK1262420B (en) Composition for inducing differentiation and protection of neural stem cells and method for inducing neuro-regeneration using the same composition
HK1262420A1 (en) Composition for inducing differentiation and protection of neural stem cells and method for inducing neuro-regeneration using the same composition

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
OR01 Other related matters
OR01 Other related matters